文献速递糖尿病

血糖新型生化标志物预测1型糖尿病妊娠结局

Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2021-01-25

结果显示,HbA1c和CGM指标(尤其是目标范围内时间TIR和高于范围时间TAR)在24周与结局显著相关,而新型标志物预测能力总体低于HbA1c,未显著增加预测价值。

要点

  • HbA1c仍是预测1型糖尿病妊娠结局的重要生物标志物。
  • CGM指标中TIR和TAR是最一致的预测指标。
  • 新型生化标志物预测能力低于HbA1c,未显著提升预测。

核心结论

  • HbA1c仍是预测1型糖尿病妊娠产科和新生儿结局的重要生物标志物。
  • 新型血糖生化标志物和其他CGM指标与广泛可用的HbA1c和日益普及的CGM指标(TIR和TAR)相比,未显著增加对妊娠结局的预测。

研究设计与样本

  • 在妊娠约12、24、34周比较HbA1c、CGM数据及新型生化标志物(糖化CD59、1,5-脱水葡萄糖醇、果糖胺、糖化白蛋白)。
  • 使用逻辑回归和ROC曲线预测妊娠并发症(子痫前期、早产、大于胎龄儿、新生儿低血糖、新生儿重症监护入院)。

主要发现

  • 在妊娠24周,HbA1c、CGM指标和新型实验室标志物均与产科和新生儿结局显著相关。
  • 在妊娠早期,更多结局与CGM指标相关;在妊娠晚期,更多结局与实验室标志物相关(ROC曲线下面积一般<0.7)。
  • TIR(63-140 mg/dL [3.5-7.8 mmol/L])和TAR(>140 mg/dL [>7.8 mmol/L])是最一致的预测性CGM指标。
  • HbA1c也是不良妊娠结局的一致预测指标。
  • 一些新型实验室标志物显示出潜力,但总体预测能力低于HbA1c。

临床怎么用

  • 在1型糖尿病妊娠中,HbA1c仍应作为预测产科和新生儿结局的核心生物标志物。
  • CGM指标中的TIR和TAR可作为一致的预测工具用于临床监测。
  • 新型生化标志物目前不建议替代HbA1c或CGM指标用于预测妊娠结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal method of monitoring glycemia in pregnant women with type 1 diabetes remains controversial. This study aimed to assess the predictive performance of HbA1c, continuous glucose monitoring (CGM) metrics, and alternative biochemical markers of glycemia to predict obstetric and neonatal outcomes. RESEARCH DESIGN AND METHODS: One hundred fifty-seven women from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) were included in this prespecified secondary analysis. HbA1c, CGM data, and alternative biochemical markers (glycated CD59, 1,5-anhydroglucitol, fructosamine, glycated albumin) were compared at ∼12, 24, and 34 weeks' gestation using logistic regression and receiver operating characteristic (ROC) curves to predict pregnancy complications (preeclampsia, preterm delivery, large for gestational age, neonatal hypoglycemia, admission to neonatal intensive care unit). RESULTS: HbA1c, CGM metrics, and alternative laboratory markers were all significantly associated with obstetric and neonatal outcomes at 24 weeks' gestation. More outcomes were associated with CGM metrics during the first trimester and with laboratory markers (area under the ROC curve generally <0.7) during the third trimester. Time in range (TIR) (63-140 mg/dL [3.5-7.8 mmol/L]) and time above range (TAR) (>140 mg/dL [>7.8 mmol/L]) were the most consistently predictive CGM metrics. HbA1c was also a consistent predictor of suboptimal pregnancy outcomes. Some alternative laboratory markers showed promise, but overall, they had lower predictive ability than HbA1c. CONCLUSIONS: HbA1c is still an important biomarker for obstetric and neonatal outcomes in type 1 diabetes pregnancy. Alternative biochemical markers of glycemia and other CGM metrics did not substantially increase the prediction of pregnancy outcomes compared with widely available HbA1c and increasingly available CGM metrics (TIR and TAR).

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Meek CL, Tundidor D, Feig DS, et al. Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes. Diabetes Care. 2021. PMID: 33495292. doi:10.2337/dc20-2360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。